Evidence map›Paper›PMID 32938850›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Clinical Utility of the Meal Tolerance Test in the Care of Patients with Type 2 Diabetes Mellitus.

Hisao Wakasaki, Takeshi Shono, Ryutaro Nakao, Shohei Yamamoto, Takamasa Minaga, Sakiko Fukuda, Reika Matsumoto, Takashi Ohoshi, Keigo Naka, Kishio Nanjo

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Processing Alaska Pollock Protein (Foods (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hisao WakasakiDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Takeshi ShonoDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Ryutaro NakaoDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Shohei YamamotoDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Takamasa MinagaDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Sakiko FukudaDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Reika MatsumotoDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Takashi OhoshiDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Keigo NakaDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Kishio NanjoDepartment of Internal Medicine, Wakayama Rosai Hospital, Japan.
Wakayama Rosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective The measurement of C-peptide immunoreactivity (CPR) is essential for evaluating the pancreatic β-cell function and selecting appropriate therapeutic agents in patients with diabetes mellitus. The meal tolerance test (MTT) is simple to administer physiological insulin-stimulating test. Previous studies have reported that several CPR-related indices are useful markers for predicting insulin requirement in type 2 diabetes. In the present study, we investigated the serum CPR response during the MTT in hospitalized patients with type 2 diabetes mellitus in order to clarify the clinical utility of the MTT. Methods We performed the MTT using a test meal with timed measurements of the serum CPR level based on the oral glucose tolerance test over 180 minutes and tested the correlation of various CPR-related indices and clinical factors in patients with type 2 diabetes mellitus. Patients The subjects were patients with type 2 diabetes mellitus who had been admitted to our hospital for diabetes management and education. The final study population consisted of 68 patients. Results The fasting CPR level was correlated with the 24-hour urinary CPR excretion and body mass index. The serum CPR level at 120 minutes in the MTT was strongly correlated with the area under the curve of CPR during the MTT. The patients who needed insulin therapy at 6 months after hospitalization showed a significant lower incremental CPR value from 0 to 120 minutes in the MTT than those who did not need insulin therapy. Conclusion The plasma C-peptide levels at 0 and 120 minutes in the MTT provide essential information for the clinical management of patients with type 2 diabetes mellitus.

Indexed as

Diagnostic Techniques, EndocrineAdultBiomarkersBlood GlucoseBody Mass IndexC-PeptideDiabetes Mellitus, Type 2FemaleGlucose Tolerance TestHumansHypoglycemic AgentsInsulinInsulin-Secreting CellsMaleMealsMeatBiomarkersBlood GlucoseC-PeptideHypoglycemic AgentsInsulinC-peptidemeal tolerance testtype 2 diabetes

Identifiers

PMID32938850
PMCPMC7578608
OpenAlexW3086252074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.